课题基金 / 基金详情

Development of clinical candidate hypoxia-activated DNA-PK inhibitors

Development of clinical candidate hypoxia-activated DNA-PK inhibitors
临床候选缺氧激活 DNA-PK 抑制剂的开发
批准号：
490356
负责人：
Minchinton Andrew I
金额：
$71.33万
依托单位：
B.C. Cancer Research Centre (Vancouver)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2023
资助国家：
加拿大
项目状态：
未结题
起止时间：
2023-09-01 至 2027-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=490356&lang=en
关键词：
Chemotherapy Clinical Drug Development Dna Damage Repair Inhibitors Dna-Pk Hypoxia Prodrug Prodrugs Radiotherapy Screening Cascade Tumour Microenvironment

项目摘要

项目成果

Minchinton Andrew I的其他基金

相似基金

相关文献

中文摘要
翻译
放疗和化疗仍然是无法手术的癌症的主要治疗方法。在这些疗法之后，癌细胞会被杀死，但由于它们修复DNA损伤的能力，一些癌细胞会产生抗药性。最近，药物可以阻止癌细胞的能力
英文摘要
Radiation and chemotherapy remain the principal treatments for inoperable cancers. Cancer cells are killed following these therapies, but some are resistant due to their ability to repair the DNA damage. Recently, drugs that can block a cancer cell's abil
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
FLASH radiotherapy - mechanisms and translational studies
Metabolic manipulation of hypoxia for improved radiotherapy response
Hypoxia-activated DNA repair inhibitors to improve cancer therapy
Hypoxia-selective inhibitors of DNA repair
海外基金